Nektar Therapeutics Dossier
Qualitative Analysis
Business overview
Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company focused on discovering and developing novel immunomodulatory agents in the field of immunotherapy. The company's pipeline targets autoimmune diseases and cancer, utilizing its proprietary polymer conjugate chemistry and protein engineering platforms. Its lead drug candidate is rezpegaldesleukin (REZPEG), a potential first-in-class regulatory T-cell (Treg) agonist designed to selectively stimulate Treg cells to restore immune system balance in patients with autoimmune and inflammatory disorders. Other pipeline candidates include NKTR-0165 (a TNFR2 agonist antibody), NKTR-0166, NKTR-422, and NKTR-255.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing the lead regulatory T-cell (Treg) stimulator, rezpegaldesleukin (REZPEG / NKTR-358), into Phase 3 development for atopic dermatitis and aligning on a Phase 3 path for alopecia areata.
Expected impact: Establishes rezpegaldesleukin as a late-stage, potentially first-in-class disease-modifying biologic for autoimmune dermatology indications.
Advancing early-stage and preclinical candidates, including NKTR-0165 (a TNFR2 agonist antibody for multiple sclerosis) and NKTR-422 (a CSF1R agonist biologic for acute/chronic inflammation).
Expected impact: Diversifies Nektar's clinical pipeline beyond its lead asset, reducing binary clinical risk.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Collaborating to evaluate NKTR-0165, a tumor necrosis factor receptor 2 (TNFR2) antibody, for the treatment of multiple sclerosis.
Terms: Specific financial terms of the academic research collaboration were not disclosed.